PremiumThe FlyErasca announces IND clearance, prioritizing of RAS-targeting franchise Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating Erasca presents new RAS-targeting franchise data at AACR meeting PremiumThe FlyErasca reports Q4 EPS (11c), consensus (13c) ERAS Earnings this Week: How Will it Perform? Erasca assumed with an Overweight at Morgan Stanley PremiumCompany AnnouncementsErasca, Inc. Reports Strong Progress in Oncology Pipeline Erasca reports Q3 EPS (11c), consensus (17c) Erasca announces clinical progress for naporafenib